Alnylam Pharmaceuticals
ALNY
#759
Rank
$32.18 B
Marketcap
$240.51
Share price
-2.52%
Change (1 day)
-47.26%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): $5.53

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is $5.53. In 2025 the company made an earnings per share (EPS) of $2.06.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)$5.53168.45%
2025$2.06
2023-$3.53-62%
2022-$9.2929.03%
2021-$7.20-3.36%
2020-$7.45-8.48%
2019-$8.147.67%
2018-$7.5639.74%
2017-$5.4112.94%
2016-$4.7938.84%
2015-$3.45-32.88%
2014-$5.14259.44%
2013-$1.43-31.25%
2012-$2.08

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
$6.66 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$1.90-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
$41.91 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-$2.63-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-$0.73-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-$0.09000-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
$0.63-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-$3.33-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA